Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

被引：33

作者：

Kuppen, Malou C. P. ^{[1
]}

Westgeest, Hans M. ^{[2
]}

van der Doelen, Maarten J. ^{[3
]}

van den Eertwegh, Alphonsus J. M. ^{[4
]}

Coenen, Jules L. L. M. ^{[5
]}

Aben, Katja K. H. ^{[6
,7
]}

van den Bergh, Alphons C. M. ^{[8
]}

Bergman, Andries M. ^{[9
]}

van den Bosch, Joan ^{[10
]}

Celik, Filiz ^{[11
]}

Hendriks, Mathijs P. ^{[12
]}

Lavalaye, Jules ^{[13
]}

van der Meer, Saskia ^{[14
]}

Polee, Marco B. ^{[15
]}

Somford, Diederik M. ^{[16
]}

van Oort, Inge M. ^{[17
]}

Uyl-de Groot, Carin A. ^{[1
]}

Gerritsen, Winald R. ^{[3
]}

机构：

[1] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Inst Med Technol Assessment, Rotterdam, Netherlands

[2] Amphia Hosp, Dept Internal Med, Breda, Netherlands

[3] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands

[4] Vrije Univ, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands

[5] Isala, Dept Oncol, Zwolle, Netherlands

[6] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, Nijmegen, Netherlands

[7] Netherlands Comprehens Canc Org, Utrecht, Netherlands

[8] Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands

[9] Netherlands Canc Inst, Div Internal Med MOD & Oncogen, Antoni van Leeuwenhoek Hosp, Amsterdam, Netherlands

[10] Albert Schweitzer Ziekenhuis, Dept Internal Med, Dordrecht, Netherlands

[11] Deventer Hosp, Dept Nucl Med, Deventer, Netherlands

[12] Northwest Clin, Dept Internal Med, Alkmaar, Netherlands

[13] St Antonius Hosp, Dept Nucl Med, Nieuwegein, Netherlands

[14] Jeroen Bosch Hosp, Dept Urol, sHertogenbosch, Netherlands

[15] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands

[16] Canisius Wilhelmina Hosp, Dept Urol, Nijmegen, Netherlands

[17] Radboud Univ Nijmegen, Dept Urol, Med Ctr, Nijmegen, Netherlands

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 19期

关键词：

metastatic castration-resistant prostate cancer; radium-223; real-world outcomes; sequencing; skeletal-related events; survival; BONE METASTASES; DOUBLE-BLIND; THERAPY; PHASE-3; TRIAL; RECOMMENDATIONS; EXPERIENCE; EFFICACY; EVENTS; CYCLES;

D O I：

10.2217/fon-2020-0039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line >= 3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line >= 3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

引用

页码：1371 / 1384

页数：14

共 50 条

[1] Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study
Hyvakka, Anniina
Kaariainen, Okko-Sakari
Utriainen, Tapio
Loyttyniemi, Eliisa
Mattila, Kalle
Reinikainen, Petri
Sormunen, Jorma
Jaaskelainen, Minna
Auvinen, Paivi
Minn, Heikki
Sundvall, Maria
CANCER MEDICINE, 2023, 12 (04): : 4064 - 4076
[2] Radium-223 for metastatic, castration- resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan
Weng, Wei -Chun
Huang, Li-Hua
Tseng, Neng-Chuan
Ou, Yen-Chuan
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (10) : 1929 - 1937
[3] Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging
Iizuka, Junpei
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 16 - 23
[4] Radium-223 in metastatic castration resistant prostate cancer
Vuong, Winston
Sartor, Oliver
Pal, Sumanta K.
ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (03) : 348 - 353
[5] Radium-223 Dichloride for Metastatic Castration-resistant Prostate Cancer: The Urologist's Perspective
Shore, Neal D.
UROLOGY, 2015, 85 (04) : 717 - 724
[6] Radium-223 dichloride for the treatment of metastatic prostate cancer
Turner, Philip Geoffrey
O'Sullivan, Joe
EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (14) : 2105 - 2111
[7] Radium-223 dichloride in patients with castration-refractory prostate cancer
Winter, B. M.
von Rundstedt, F. -C.
Grimm, M. -O.
UROLOGE, 2017, 56 (11): : 1435 - 1439
[8] Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
Vidal, Monica
Delgado, Alejandro
Martinez, Carlos
Jaime Correa, Jose
Cristina Durango, Isabel
INTERNATIONAL BRAZ J UROL, 2020, 46 (04): : 599 - 611
[9] Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases
Vogelzang, Nicholas J.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (08) : 809 - 819
[10] Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study
Matsumoto, Takashi
Hori, Yoshifumi
Shiota, Masaki
Blas, Leandro
Nakamura, Motonobu
Seki, Narihito
Kuroiwa, Kentaro
Yokomizo, Akira
Morokuma, Futoshi
Kiyoshima, Keijiro
Eto, Masatoshi
INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (02) : 139 - 146

← 1 2 3 4 5 →